JBC Transcription and Nuclear Factor Monoclonals

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M401208200 on June 24, 2004

J. Biol. Chem., Vol. 279, Issue 35, 36490-36496, August 27, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
279/35/36490    most recent
M401208200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, S.
Right arrow Articles by Houghton, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, S.
Right arrow Articles by Houghton, P. J.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Inhibition of Mammalian Target of Rapamycin Activates Apoptosis Signal-regulating Kinase 1 Signaling by Suppressing Protein Phosphatase 5 Activity*

Shile Huang{ddagger}§, Lili Shu{ddagger}, John Easton{ddagger}, Franklin C. Harwood{ddagger}, Glen S. Germain{ddagger}, Hidenori Ichijo||, and Peter J. Houghton{ddagger}

From the {ddagger}Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38105-2794 and the ||Laboratory of Cell Signaling, Graduate School of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan

Under serum-free conditions, rapamycin, an inhibitor of mammalian target of rapamycin (mTOR), induces a cellular stress response characterized by rapid and sustained activation of the apoptosis signal-regulating kinase 1 (ASK1) signaling pathway and selective apoptosis of cells lacking functional p53. Here we have investigated how mTOR regulates ASK1 signaling using p53-mutant rhabdomyosarcoma cells. In Rh30 cells, ASK1 was found to physically interact with protein phosphatase 5 (PP5), previously identified as a negative regulator of ASK1. Rapamycin did not affect either protein level of PP5 or association of PP5 with ASK1. Instead, rapamycin caused rapid dissociation of the PP2A-B'' regulatory subunit (PR72) from the PP5-ASK1 complex, which was associated with reduced phosphatase activity of PP5. This effect was dependent on expression of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1). Down-regulation of PP5 activity by rapamycin coordinately activated ASK1, leading to elevated phosphorylation of c-Jun. Amino acid deprivation, which like rapamycin inhibits mTOR signaling, also inhibited PP5 activity, caused rapid dissociation of PR72, and activated ASK1 signaling. Overexpression of PP5, but not the PP2A catalytic subunit, blocked rapamycin-induced phosphorylation of c-Jun, and protected cells from rapamycin-induced apoptosis. The results suggest that PP5 is downstream of mTOR, and positively regulated by the mTOR pathway. The findings suggest that in the absence of serum factors, mTOR signaling suppresses apoptosis through positive regulation of PP5 activity and suppression of cellular stress.


Received for publication, February 3, 2004 , and in revised form, June 18, 2004.

* This work was supported in part by United States Public Health Service awards CA77776 (to P. J. H.), CA96696 (to P. J. H.), CA23099 (to P. J. H.), and CA28765 (Cancer Center Support Grant) (to P. J. H.) from the NCI, National Institutes of Health, by a grant from WyethAyerst Company (to P. J. H.), by a grant-in-aid award (to S. H.), and a start-up fund (to S. H.) jointly from Louisiana State University Health Sciences Center in Shreveport and Feist-Weiller Cancer Center in Shreveport, LA, and American, Lebanese, Syrian-associated Charities (ALSAC) in Memphis, TN. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ Present address: Dept. of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center,1501 Kings Highway, Shreveport, LA 71130-3932.

To whom correspondence should be addressed: Dept. of Molecular Pharmacology, St. Jude Children's Research Hospital, 332 Lauderdale, Memphis, TN 38105-2794. Tel.: 901-495-3440; Fax: 901-495-4290; E-mail: peter.houghton{at}stjude.org.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
F. C. Harwood, L. Shu, and P. J. Houghton
mTORC1 Signaling Can Regulate Growth Factor Activation of p44/42 Mitogen-activated Protein Kinases through Protein Phosphatase 2A
J. Biol. Chem., February 1, 2008; 283(5): 2575 - 2585.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
C. Gridelli, P. Maione, and A. Rossi
The Potential Role of mTOR Inhibitors in Non-Small Cell Lung Cancer
Oncologist, February 1, 2008; 13(2): 139 - 147.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
J. Zhan, J. B. Easton, S. Huang, A. Mishra, L. Xiao, E. R. Lacy, R. W. Kriwacki, and P. J. Houghton
Negative Regulation of ASK1 by p21Cip1 Involves a Small Domain That Includes Serine 98 That Is Phosphorylated by ASK1 In Vivo
Mol. Cell. Biol., May 1, 2007; 27(9): 3530 - 3541.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
E. F. Petricoin III, V. Espina, R. P. Araujo, B. Midura, C. Yeung, X. Wan, G. S. Eichler, D. J. Johann Jr., S. Qualman, M. Tsokos, et al.
Phosphoprotein Pathway Mapping: Akt/Mammalian Target of Rapamycin Activation Is Negatively Associated with Childhood Rhabdomyosarcoma Survival
Cancer Res., April 1, 2007; 67(7): 3431 - 3440.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. T. Teachey, D. A. Obzut, K. Axsom, J. K. Choi, K. C. Goldsmith, J. Hall, J. Hulitt, C. S. Manno, J. M. Maris, N. Rhodin, et al.
Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS)
Blood, September 15, 2006; 108(6): 1965 - 1971.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H.-G. Wendel, A. Malina, Z. Zhao, L. Zender, S. C. Kogan, C. Cordon-Cardo, J. Pelletier, and S. W. Lowe
Determinants of Sensitivity and Resistance to Rapamycin-Chemotherapy Drug Combinations In vivo.
Cancer Res., August 1, 2006; 66(15): 7639 - 7646.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. T. Teachey, D. A. Obzut, J. Cooperman, J. Fang, M. Carroll, J. K. Choi, P. J. Houghton, V. I. Brown, and S. A. Grupp
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL
Blood, February 1, 2006; 107(3): 1149 - 1155.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. Zhou, T. Golden, I. V. Aragon, and R. E. Honkanen
Ser/Thr Protein Phosphatase 5 Inactivates Hypoxia-induced Activation of an Apoptosis Signal-regulating Kinase 1/MKK-4/JNK Signaling Cascade
J. Biol. Chem., November 5, 2004; 279(45): 46595 - 46605.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.